New Venture Fund Closes $102M to Boost Biotech and Medical Device Development

Truffle Capital has raised $102M (€85M), which will support biotechs, with a focus on medical device companies that have the potential to become market leaders.

Truffle Capital, founded in 2001 and based in Paris, is a venture capital firm that focuses on supporting start-ups in life sciences and IT. The company manages assets worth over $1.1B (€920M) and has funded over 80 companies, including Carmat, Carbios, and Abivax, since its inception. It has closed its most recent fund, Truffle BioMedTech, which was supported by European and Asian investors, as well as family offices. However, the fundraising is not over, with Truffle confident of reaching its target of $240M (€200M) by the end of 2018.

Philippe Pouletty, CEO and co-founder of Truffle Capital, revealed that the company not only provides investment to young companies but also “sets up an ambitious R&D team, an experienced management team, and attracts co-investors to promote growth to advanced clinical, manufacturing and commercial stages.” This will only add to the excitement in the biotech industry, with Boehringer Ingelheim doubling the size of its venture fund to 250M, Hadean Ventures raising €100M, and LSP closing the continent’s largest medtech fund worth €280M all in the past month.


Image – Olga Larionova / shutterstock.com

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.